ArticleTheranostics2020
Genome-wide interaction target profiling reveals a novel
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Widespread impact of nucleosome remodelers on transcription at cis-regulatory elements.Cell reports · 2025Article
- A specific pluripotency-associated eRNA controls Nanog locus by shaping the epigenetic landscape and stabilizing enhancer-promoter interaction.Nucleic acids research · 2025Article
- Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness.Cells · 2025Review
- Active enhancers: recent research advances and insights into disease.Biology direct · 2024Review
- Profiling mitochondria-polyribosome lncRNAs associated with pluripotency.Scientific data · 2023Article
- Chromatin-RNA in situ Reverse Transcription Sequencing (CRIST-seq) Approach to Profile the Non-coding RNA Interaction Network.Bio-protocol · 2023Article
- LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Differential Expression of Non-Coding RNAs in Stem Cell Development and Therapeutics of Bone Disorders.Cells · 2023Review
- BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists.Journal of translational medicine · 2023Article
- Epigenetic reprogramming during prostate cancer progression: A perspective from development.Seminars in cancer biology · 2022Review
- The roles of long noncoding RNAs in the regulation of OCT4 expression.Stem cell research & therapy · 2022Review
- Functional interplay between long non-coding RNAs and Breast CSCs.Cancer cell international · 2022Review
- Review
- Enhancer RNA: What we know and what we can achieve.Cell proliferation · 2022Review
- LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond.Journal of experimental & clinical cancer research : CR · 2022Review
- Chromatin lncRNA Platr10 controls stem cell pluripotency by coordinating an intrachromosomal regulatory network.Genome biology · 2021Article
- Functional roles of antisense enhancer RNA for promoting prostate cancer progression.Theranostics · 2021Article
- Non-Coding RNAs and Nucleosome Remodeling Complexes: An Intricate Regulatory Relationship.Biology · 2020Review
- Oplr16 serves as a novel chromatin factor to control stem cell fate by modulating pluripotency-specific chromosomal looping and TET2-mediated DNA demethylation.Nucleic acids research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.